Medtech firm takes on a giant partner
MEDTECH start-up firm Gendius has partnered with AstraZeneca to develop its diabetes management platform.
The Alderley Park company and the pharmaceutical giant have signed a ‘memorandum of understanding’ for Intellin, which has more than 200,000 downloads worldwide.
Intellin supports patients in the Middle East, which has some of the highest rates of diabetes in the world.
Through the partnership, healthcare professionals in the region will use the platform to help reduce diabetes complications, which can include blindness, kidney disease and amputation.
The agreement is part of AstraZeneca’s emerging markets health innovation hubs initiative.
Rory Cameron, from Gendius, said: “Diabetes is an increasing health and economic burden across the Gulf region, but effective diabetes management has huge scope for reducing that burden.
“Our technology platform is going to sit at the centre of this program, and we are hugely excited to be bringing our technology directly to healthcare professionals and patients.”
Aleksandr Bedenkov, from AstraZeneca, said: “We are very excited about this collaboration that will support diabetes patients and facilitate the disease management.”
The Intellin platform uses artificial intelligence to monitor patients’ diabetes management and uses their clinical history to highlight their risk for developing diabetes-related complications.